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Abstract
Background: Polypharmacy, defined as the use of five or more medications, has the
potential to increase morbidity, mortality and decrease quality of life. Older adults are
disproportionately affected by polypharmacy. Decreasing polypharmacy could prevent
morbidity and mortality while saving millions of dollars annually. The use of the
ARMOR tool has been shown to decrease polypharmacy and the prescribing of
inappropriate medications among the elderly.
Local problem: There is a high prevalence of polypharmacy among older adult patients
at the managed care organization where this quality improvement project was
implemented. Among a panel of 30 members, almost all (n=29) were taking at least 10
medications.
Methods: The ARMOR tool, was implemented using a polypharmacy deprescribing
protocol among older adults in a community-based care organization. This quality
improvement project tested the feasibility, acceptability, and effectiveness of the
ARMOR tool among older adults enrolled in a managed care organization in
Massachusetts. Older patients taking 10 or more medications were eligible for a
multidisciplinary team-based review using the ARMOR tool. The ARMOR tool was used
as a guide using sequential steps in deciding whether medications should be discontinued.
Intervention: The ARMOR tool was used to enhance knowledge and deprescribe as
necessary with primary care provider approval. During the twelve-week implementation,
older adults taking 10 or more medications were screened using the ARMOR tool’s
criteria. The clinical pharmacist was consulted as necessary.
Results: Following the implementation of the ARMOR step by step process, there was a
meaningful decrease in polypharmacy for those participants who could complete all
phases of the tool. Thirty patients were deemed eligible for the pathway; 30% (n=9) were
able to complete all phases of the ARMOR tool. Of these nine members, there was an 18
percent decrease in the number of medications prescribed.
Summary: For those patients in whom the full ARMOR tool could be implemented;
there was a clinically significant improvement in polypharmacy. However, in the
majority of patients, clinicians were not able to complete the final step in the ARMOR
tool which was to coordinate deprescribing with the PCP. Education about
polypharmacy and organizational changes to partner with primary care providers around
polypharmacy is needed.

Keywords: ARMOR tool, polypharmacy, older adults, deprescribing tools, prescription
of inappropriate prescribing, drug interactions, adverse drug events.
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Introduction
Polypharmacy is a significant problem for both the elderly and the healthcare
system. An increase in the number of medications that are taken, especially if an elderly
patient is taking five or more medications increases the risk for adverse drug events:
including adverse drug interactions, medication non-adherence, and reduced functional
capacity such as neurological impairments and increase incidents of falls.
Despite the high prevalence and known issues, there is no real consensus
definition of polypharmacy, although it is commonly accepted as five or more
medications (Masnoon et al., 2017). The term polypharmacy is often used when multiple
medications are used by a patient or when more drugs are prescribed than clinically
necessary (Haque, 2009). Eighty percent of the elderly are on as many as seven
medications while fifty eight percent takes five or more (Cantlay et al., 2016).
Polypharmacy and associated adverse drug events were responsible for approximately
100,000 emergent hospitalizations in the older adult population and approximately 136
billion dollars are spent annually on the treatment of over 2 million adverse drug events
(Terrery & Nicoteri, 2016). Polypharmacy and the use of inappropriate drugs have
immediate consequences on drug interactions, adverse effects, higher frequency of
required healthcare visit, and functional outcomes.
The number of older adults dealing with polypharmacy is growing rapidly due to
disease-specific guidelines that recommend multiple drugs at lower doses to attain the
best possible health outcomes with the minimum of side effects (Nobili et al. 2011).
Despite public health advances that have increased the life expectancy of older adults by
30 years, the risk of developing a chronic disease increases as individuals age, which in
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turn, could lead to multiple medications being prescribed. The potential for increased
problems with polypharmacy can occur when patients are prescribed medications by
multiple healthcare providers as a result of fragmented care. System-level factors which
contribute to polypharmacy are related to poorly updated medical records, the use of
multiple specialties and lack of communications between providers, automatic refills of
medications that have already been discontinued by providers and the lack of consistency
in using just one pharmacy (Halli et al., 2019).
Local Problem
At the organization where the project was carried out, there is a high prevalence
of polypharmacy among the elderly members. A preliminary review of one provider’s
panel of 72 members revealed that of the 30 members who were ages 60 and older, every
member (n=30) was on ten or more medications, and most were taking in excess of 10
medications a day. Of note, 16 members (52%) were taking 10 to 19 medications, eight
members (28%) were taking between 24 to 27 medications and six (20%) were taking 31
medications. This illustrates the complexity and the magnitude of the polypharmacy issue
among patients seen at this organization.
The factors associated with polypharmacy at the site managed care organization
include but are not limited to a lack of protocol to identify members that are on 10 or
more medications and multiple comorbidities. Due to the volume of members served by
each clinician, it can be challenging to manage member’s polypharmacy without a set
protocol in place and the collaboration of each team and primary care provider (PCP).
Active collaboration is needed between the PCP’s and the clinicians at this organization
to better manage polypharmacy for all members that are 60 years of age and older.
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Available Knowledge
A Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guided literature search examined effective strategies for reducing
polypharmacy. The databases searched included: Cumulative Index to Nursing and Allied
Health Literature (CINAHL), Cochrane, OVID, and NLM journal articles database
(PUBMED). The key terms used were ARMOR tool, polypharmacy, older adults,
deprescribing tools, prescription of inappropriate prescribing, drug interactions, adverse
drug events.
To identify potential solutions to decreasing polypharmacy, the literature search
focused on answering the PICO question, “Among older adults aged 60 and older, what
strategies have been shown to decrease polypharmacy?”
Deprescribing is an important step in making sure medications are reconciled effectively,
and in ensuring safety, and preventing prescribing cascades. There are several literature
reviews and guidelines that show how polypharmacy is higher in older individuals and
those with complex morbidities and highlight the negative correlation with prescription
of inappropriate medication (PIM) and polypharmacy. Best et al. (2013) agree that trends
of polypharmacy in the elderly often ended up in incomplete medical histories and
mistakenly, providers end up prescribing more medications than needed, thereby
increasing the problem of polypharmacy.
Complex medication regimens can sometimes be a burden even in the most
committed patients. Cadogan et al., 2016) state the concern of polypharmacy may be
resolved through a step-by-step protocol like the ARMOR tool. It is recommended for
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providers to advise patients to only take medications that have been prescribed, as this
will reduce chances of drug-drug interactions (Nawaz et al., 2015). The use of Proper
protocol or procedure has improved adherence to medication regimens (Nawaz et al.,
2015). Many clinicians are familiar with the Beer’ s Criteria ((Dagli & Sharma, 2014),
but may not be familiar with other guidelines/tools such as the Assess, Review,
Minimize, Optimize, and Reassess [ARMOR] tool.
The ARMOR tool was developed to aid in evaluating and protecting patients from
prescriptions of inappropriate and possible harmful medications in the elderly
population. It focuses on identifying the indication and efficacy for medications (Witticke
et al., 2013). It takes into consideration the patient's overall medical plan and functional
status. The ARMOR tool also takes a closer look at a patient’s quality of life prior to
making decisions on decreasing or discontinuing medications. The use of the ARMOR
tool requires an effective multidisciplinary approach which includes involvement from
nurses, providers, pharmacists, and physical therapists as needed.
Several studies report that the application of the ARMOR tool has led to a
considerable reduction in polypharmacy, reduction of cost of care, and decrease in
hospitalization in settings where it was implemented as part of a quality improvement
project (Dagli & Sharma, 2009; Haque, 2009). The ARMOR framework provides a stepby-step and structured approach for a thorough analysis of current medications taken
while accounting for most of the prescription’s aspects. The ARMOR tool incorporates
the Beer criteria in the assessment phase of deprescribing Dagli & Sharma (2014).
Residents showed a decline in the frequency of falls and other harms when the use
of the ARMOR tool was used to reduce unnecessary medications (Haque, 2009).
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Additionally, the ARMOR tool supports the idea of optimizing and re-evaluating the riskbenefit of any pharmacological agent and possible drug-body and drug to drug interaction
(Sechana et Rashmi, 2020).
This review of the evidence suggests that the ARMOR tool can be useful in
decreasing the number of medications being prescribed which in turn has been found to
decrease drugs and adverse events; and to promote an efficient and intentional approach
for a systematic analysis of medications while being deliberate about most of the
prescribing aspects in improving quality of life of the patient. Equally important, the tool
fits with the needs of the organization where this improvement project was undertaken.
Therefore, implementation of the ARMOR tool will be the foundation for the project
intervention.

Rationale
This project was guided by the Evolution of Care [EMOC] model which is
utilized at the organization where the improvement project was carried out. The model
emphasizes the need for in-depth comprehensive health delivery processes in order to
successfully implement complex interventions in the homecare setting. In alignment with
EMOC, the organization provides quality, compassionate care that meets the unique
needs of each member. This approach to care is based on every member having a
dedicated team to coordinate all aspects of their care plan. Care is delivered in
interdisciplinary teams with clinical and nonclinical caregivers chosen to meet the
member's needs. This care model focuses on including members and their families in the
day-to-day planning of current and future care according to their goals and wishes.
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Clinician’s such as advance practice providers and registered nurses are available to assist
with home visits for members that are not able to participate in telehealth. Members can
improve their quality of life and stay in their home, or other settings, of their choosing.
The process of implementing this change project was guided by Kurt Lewin’s
Change Management Model in the 1940s. This model helps in understanding innovative
organizational change (Bozak, 2003). The Unfreeze – Change – Refreeze refers to the
three-stage process of change. The theory suggests providers in a busy workplace setting
are subject to forces that resist change and often deter the need to follow guidelines
closely.
The Lewin’s change theory for this quality improvement project was chosen to
guide and improve the prescribing process in adults 60 and older using the ARMOR tool
and in turn decrease polypharmacy and deprescribing of inappropriate medications. To
initiate change, discussions initially started about the restraining or static forces that
prevented change and focused on unfreezing those forces. Some restraining forces
identified were providers resistance to changing prescribing patterns, lack of knowledge
of implementing the ARMOR tool, newer providers not having the necessary skills to
initiate discussions about polypharmacy in older adults, high workload and time
constraints. During the unfreezing stage, polypharmacy was identified as a priority
problem. (Bozak, 2003).
Based on the evidence and fit with the organization, the project will implement
the ARMOR tool to assess opportunities for deprescribing.
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Specific Aims
The purpose of this improvement project was to decrease polypharmacy and the
prescription of inappropriate medications among older adults enrolled in a communitybased care program. The overarching goal was to design, implement and evaluate a
deprescribing pathway, and empower prescribing clinicians in using the ARMOR tool.
These goals were accomplished by the following objectives:
Objectives:
1.

Identify 30 community dwelling elders’ age 60 or older on 10 or more
medications and bring them to huddle.

2. The ARMOR tool will be used to assess all 30 identified patients who met criteria
of polypharmacy and a list of recommendations regarding the medication regimen
will then be sent to the primary care provider for review and approval.
3. Medication use will be reduced by at least 10% for this group of community
dwelling elders.

Methods
Context
This project took place at a not-for-profit community-based healthcare
organization devoted to better the health of individuals who are dually eligible for
MassHealth (Medicaid) and Medicare. Most of the eligible members have complex
medical, behavioral health and social needs, as well as some physical disabilities. This
organization offers two types of health plans: One Care program for dual eligible
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individuals ages 21 to 64 and Senior Care options for individuals ages 65 and over who
have Medicare and Medicaid as well as four different sites across the state.
This organization provides members with a comprehensive range of services that
includes preventive care, medical and dental care, behavioral health care, durable medical
equipment, and social services and supports. Utilizing The EMOC model provides an
individualized, patient-centered, and comprehensive plan of care. Each member has a
dedicated care manager (usually a registered nurse if the primary diagnosis is medical
and a social worker if the primary problem is behavioral health) and a care team that
includes advance practice clinicians, registered nurses, licensed social workers,
occupational and physical therapists, and pharmacists who meet on a daily basis to
discuss patients. The care manager coordinates patient-specific services wherever the
member needs them, whether at their home, via video/telehealth or in a medical office.
The microsystem assessment found in Appendix (G) provides additional context for the
organization.
Using a cause-and-effect diagram to illustrate the factors associated with
polypharmacy in patients care Appendix (B) the primary cause identified was the lack of
a centralized process to manage members that are on ten or more medications. Although
there is a team pharmacist available for consults as needed, the pharmacists are not
identifying or overseeing all the members that are on ten or more medications. The
pharmacists are working independently through this process and the team advance
practice clinicians are not being utilized. There are currently no policies or written
process that identifies or targets members on ten or more medications or to identify the
need to deprescribe with the collaboration and approval of the Primary Care provider.
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Another caveat is that the care partner for members that are on multiple
medications are not always a registered nurse. If the member’s primary problem is
behavioral health, many of the care partners are licensed social workers, who do not have
the medical knowledge to identify polypharmacy and medications that are harmful to the
members. Furthermore, on average the care partners are assigned approximately 150-250
members who are complex, medically and mentally, and must prioritize their acute needs
such as housing, ordering supplies, medications refill throughout the day. These factors
make it difficult for the assigned social workers to keep track of members who are on
inappropriate medications or members that can be flagged for the possibility of
deprescribing or harmful medications.
The intervention would address key factors such as removing duplicate and highrisk medications using the ARMOR tool and the Beers criteria, streamlined, and
coordinated care between specialties, assessed functional status for each medication,
avoided adverse drug reactions and inappropriate prescribing by assessing patients as a
group and made a coordinated plan for polypharmacy.
There are several contextual factors specific to this organization that have
implications for successful implementation of this improvement project. A force field
analysis Appendix (B) was constructed to illustrate the driving and restraining forces that
will influence the success of implementing the ARMOR tool and deprescribing protocol.
A lack of buy-in to reinforce coordination between the APCs at the current organization
and the PCPs. Furthermore, there is a lack of coordinated approach that integrates all
team members which can be related to conflict in scheduling, lack of time and high case
load amongst staff members. The discussions started about the restraining or static forces
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that enhance or prevent change and focused on providing new ways of thinking and
integrating of new system of practice into existing processes. Some of the driving forces
for this quality improvement project are organizational expectations for meeting and
exceeding safety standards, needing better benchmarks for polypharmacy, monitoring
medication changes in a systematic way (using the ARMOR tool by all clinicians) and
achieving a higher level of patient safety and quality of life. Some of the restraining
forces are providers resistance to changing prescribing patterns, lack of confidence with
identifying medications that may be inappropriate, lack of skills to initiate discussions
about potential inappropriate medications, as well as time constraints. Successful
implementation helped build on the driving forces and helped manage the restraining
forces with continuous collaborations from each team member as well as the support
from leadership.
Project Intervention
The improvement project implemented a polypharmacy deprescribing
intervention using the ARMOR tool which is illustrated in Figure 1. A full- page copy of
the intervention is contained in Appendix G. The project leader, who served as the
advanced practice nurse for this project, reviewed her panel of 80 members and identified
members who are 60 and older and on 10 or more medications with complex needs and
high risk for polypharmacy based on co-morbidity. She brought these individuals up for
discussion during the interdisciplinary morning team huddle (Step 1). Next, the project
leader assessed these individuals using the ARMOR protocol (Assess, Review, Minimize,
Optimize, Reassess) using the Beer criteria (Step 2)
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Using the ARMOR tool in step 2, the 30 members brought to huddle were
evaluated by the project leader for the total number of medications they are on and for
certain groups of medications such as beta blockers, utilization of the Beers criteria, pain
medications, antipsychotics or psychotropics medications, vitamins, and supplements.
The project leader also reviewed electronic medical record and identified common over
the counter/ prescription interactions (i.e antacid medications, iron supplements, and
thyroid medications; coumadin and aspirin), any duplication of medications and any
medications that were added to treat side effects of another medications (step 3).
If the member was on fewer than 10 medications, they were not reassessed at the
morning team huddles as previously planned due to time constraints. The plan for future
PDSA cycle is to reassessed members on 10 or less medications at each subsequent
interdisciplinary team huddle to determine if they have had mediations added and now
meet the criteria for polypharmacy.
If upon the initial review, the member was on 10 or more medication, and was
brought to the team morning huddle, the Review phase of the ARMOR tool was utilized
to review possible drug-drug interactions, impact of functional status, subclinical adverse
drug reactions were weighed for individual medication benefits against appetite, mood,
weight, pain, and activity level. In Step 4, when deprescribing was needed for
unnecessary/redundant/unsafe medications, the project leader collaborated with the
primary care provider and made recommendations to minimize and optimize the
medications the member was on. Medication recommendations were based on the
member’s renal and liver function as well as adjusting dosage by considering the effects
on the patient’s body such as blood sugar, pulse, and blood pressure. Minimizing focused
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on decreasing or discontinuing nonessential medications that does not have clear
evidence for their use, as well as medications whose risk outweigh benefits and had the
potential for negative impact on primary functions. Optimizing focused on addressing
duplication and redundancy. For the individuals whose primary care provider were not
able to be reached, the individual continued their medications as prescribed (Step 4a). For
those that the primary care provider agreed with the deprescribing plan (Step 4b), the
project leader scheduled a visit with the member and/or caregiver to discuss medication
changes. After the scheduled visit was completed (step 5), the project leader contacted
the primary care provider’s office within 48 to 72 hours and discussed the outcome of the
visit. During the final step (6), reassessment of the ARMOR tool, project leader
scheduled follow up visit with member and or caregiver within 1-2 weeks to monitor
functional status, medication adherence, blood pressure monitoring, heart rate, blood
sugar level, bowel pattern, fall risk, appetite, and sleep as needed.
The patient and/or caregiver were involved in shared decision making regarding
any medications which were discontinued or changed.
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Polypharmacy ARMOR Deprescribing pathway
Step 1
Project leader reviewed a panel of 80 members and identifies 30 complex members that are 60 years
and older and on 10 medications or more and bring them for discussions to morning huddle.

Step 2
Project leader Assess member’s total medications and identified certain groups of medications such as
beta blockers, pain medications, antipsychotics or psychotropics medications, vitamins and
supplements, common OTC/ prescription interactions (antacid medications, iron supplements, thyroid
medications, members on both coumadin and aspirin, any duplication of medications and any
medications that was added to treat side effects of another medications

Step 3
Project leader Review possible drug-drug interactions, impact of functional status, subclinical adverse
drug reactions were weighed for individual medication benefits against appetite, mood, weight, pain,
activity level.

Step 4
When deprescribing was needed for unnecessary/redundant/unsafe medications, the project leader
collaborated with the primary care provider and made recommendations for Minimizing and
Optimizing the medications the member was on.

Step 4a

Step 4b

For the individuals whose primary care
provider were not able to be reached, the
individual continued their medications

For those the primary care provider agreed with
the deprescribing plan, the project leader
scheduled a visit with the member and/or
caregiver to discuss medication changes.

Step 5
After the scheduled visit, project leader contacted the primary Care Provider within 48 to 72
hours and discussed the outcome of visit.

Step 6
Project leader scheduled follow up visit with
member within 1-2 weeks to monitor
member’s blood pressure, heart rate, bowel
pattern, fall risk, appetite, and sleep.
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Implementation of the intervention
For the plan phase of this PDSA cycle, the project leader sent a copy of the
proposed QI project abstract to the clinical manager, team director and the vice president
of the manage care program to get their approval. The project was then discussed further
with the team manager during a 30-minute one-to-one session. The program manager
gave approval for the project leader to implement the ARMOR tool within the panel of
the project leader. Furthermore, the project leader met with the clinical pharmacist who
was also the site champion for 30 minutes and discussed the aim, targeted population, the
ARMOR tool, time frame of the project, the current problem of polypharmacy in the
organization and how it can be addressed.
During the “study” phase of the PDSA cycle, data related to age, sex, gender, and
the number of medications prescribed for current health problems was collected
throughout the first 6 week of this quality improvement project from the electronic health
record then analyzed for an additional 4weeks. The data collected was analyzed by the
project leader and evaluated to determine if the project outcomes and objectives were met
or if there were any unintentional effects of the intervention.
The last phase, “Act”, the project leader will translate the findings into actions
and share the results with stakeholders. The main objective is for this community-based
care organization to utilize the ARMOR tool for all medications reconciliation as part of
their practice routine to decrease polypharmacy in all individuals taking 10 or more
medications.
Evaluation of the improvement
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The ARMOR tool, appendix (G) was an integral part of the evaluation of the
intervention and utilized five phases including assess, review, minimize, optimize, and
reassess in all reachable members. To measure the efficacity and effectiveness of the
ARMOR tool in optimizing and monitoring prescription patterns during post
implementation, data collection and analysis was performed using Microsoft Excel.
Furthermore, pre and post implementation data and member’s subjective and objective
data such as cognitive status and function, vital signs, and medication compliance was
reviewed.
Measures and Analysis
Measures for the project aims and outputs were measured using both quantitative
and qualitative measures. Additionally, the logic model in appendix D and the PDSA
(Plan Do study Act) cycle guided the evaluation of the success of implementing,
evaluation, and modification of the project.
1. Objective #1, Identify 30 community dwelling elders’ age 60 or older on 10 or
more medications and bring them to huddle. Polypharmacy was defined as being on at
least 10 prescription and nonprescription medications. Evidence that 30 eligible patients
being identified was abstracted from the Electronic Health Record (EMR) and noted on a
tracking tool. The 30 members on 10 or more medications enrolled, suggested successful
accomplishment of this objective

2. Objective #2, The ARMOR tool was used to assess all 30 identified patients who
met criteria of polypharmacy and a list of recommendations regarding the medication
regimen will then be sent to the primary care provider for review and approval.
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Attainment of this objective was defined as documentation in the patients EMR that all
elements of the ARMOR tool (assessment, review, minimize, optimize, and reassess)
were met. The measure was operationalized as the proportion of intervention elements
that were implemented in relation to the number of participants. Evidence was abstracted
from documentation of the step in the chart and recorded on a project log using Microsoft
Excel. Upon successful implementation of the pathway, pre- and post-chart audits were
completed, data related to medications per member were gathered using both the total of
medications and the category or class of medication per member (See appendix F). The
primary care provider was contacted to make a judgment as to any changes needing to be
made to the older adult medication
3. Objective #3, Medication use will be reduced by at least 10% for this group of
community dwelling elders. Medication reduction was measured by comparing the
number of medications the members who participated in the QI project were on prior to
the intervention in comparison to the number of medications the participants were on
post-intervention. (See appendix F). This information was abstracted from the electronic
health record at baseline and at the end of the six-week data collection and the additional
6 weeks data evaluation and analysis. Descriptive statistics such as frequencies,
proportion, mean scores, and percentage were used to evaluate the success of this
objective. The percent improvement (reduction in medications) was measured using the
formula (# meds post intervention minus # meds pre-intervention (change) divided by the
# meds pre-intervention times 100).

Ethical Considerations
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This project was developed as a quality improvement initiative and was not used
for research purposes or designed to address a research problem. As noted in the Clinical
Quality Improvement Checklist (Appendix F), the project followed established
techniques used in quality improvement, such as PDSA, and did not follow a research
design. The project involved the implementation of an established tool, adapted to the
needs of the organization, with the purpose of improving the quality of care.
The project was discussed with the clinical manager at the community-based care
organization, who approved the project as a quality improvement project, designed to
improve the process and delivery of care and does not require IRB approval. The project
or innovation proposed is a quality improvement and does not meet the definition of
human subject’s research because it is not designed to generated generalizable findings
but rather to provide immediate and continuous improvement feedback in the local
setting in which the project is carried out. The University of Massachusetts Boston IRB
has determined that quality improvement projects do not need to be reviewed by the
IRB.

Results
The project team lead reviewed her panel of 80 patients and identified those
patients who were age 60 and older and on 10 medications. From this list, 30 patients
were identified for inclusion in this improvement project. The majority of participants
were women (57%; n=17) and all were over 60 years of age with a mean age of 62 years
(age range 60 to 76). All were dually eligible Medicare and Medicaid which is a proxy
for low socioeconomic status. The members ethnicities were not evaluated.
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These patients were brought to the team huddle, and the patient’s medications
were discussed including the assessment and review component of the ARMOR tool. The
team huddle involved two community advance practice clinicians, four care partners, one
community registered nurse and the team pharmacist, clinical director and medical
director depending on their availability. Following the huddle, the project leader further
analyzed the members medications using the optimization and minimizing phase of the
ARMOR tool. If it was determined that there were medications which could be
discontinued, the project leader called the primary care provider to discuss minimizing
polypharmacy and inappropriate medications. The aim of identify 30 members who met
the eligibility criteria for the deprescribing pathway was met.
Of the 30 members with polypharmacy brought to huddle the project leader used
the ARMOR tool to assess and review each member’s medication list including the
number and category of both prescription and over-the-counter medications they were on.
Following this review, all 30 members were considered candidates for deprescribing, and
the advanced practice nurse contacted the primary care provider to discuss optimizing
and minimizing the inappropriate medications. . . Up to this stage of the deprescribing
pathway, the project leader was able to implement the Assess and Review phase for all
members. Only nine primary care providers were reachable (30% response rate). The
goal was that 100% of eligible members would be included in all aspects of the pathway.
Although 100% (n=30) of the participants were assessed, reviewed, and ready for
optimizing and minimizing their medications, only 30 percent(N=9) completed the entire
pathway due to breakdown in communication with the primary care provider. For those
patients who completed the pathway and had medications deprescribed (n=9), the project
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leader scheduled a follow up visit within 1 week after the completion of the pathway to
reassess vital signs as well as functional and mental status. Objectively there were no
significant changes in vital signs, the vital signs were stable. Additionally, all members
appeared more engaged in their medication schedule post implementation. Subjectively,
all nine members who completed the pathway self-reported improvement in functional
and mental status. One patient was on multiple sedative medications and self-reported
improvement in functional status.
The demographic characteristics of the nine patients who participated in all steps
of the deprescribing pathway were similar to the demographic characteristics of all
eligible patients. The average number of medications pre implementation of the ARMOR
tool was 22.5 with a range of 10 to 30 medications per person. Post implementation, the
average number of
medications was 18.8
which represents a
reduction of four
medications per
person. Thus, for
those patients in
whom the complete pathway could be implemented, there was an overall improvement of
18%, which meets and exceeds the goal of reducing medications by 10%.
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14
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39
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Discussion
Summary
The aim of this quality improvement project was to decrease polypharmacy and
prescription of inappropriate medications among older adults enrolled in a communitybased managed care program.For those individuals who could be included in the full
deprescribing pathway, this aim was met. The project advanced practice clinician was
able to identify members who met the criteria of polypharmacy through an electronic
chart review and the use of the ARMOR tool guided the deprescribing of inappropriate
medications. The success of this project validated the importance of routinely reconciling
medications. This quality improvement findings revealed success in reducing
polypharmacy using the ARMOR tool and meeting the objectives of this project. The
findings demonstrate that if a deprescribing intervention based on the ARMOR tool is
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fully implemented that members within a community-based care organization who are
identified with polypharmacy can reduce the number of medications prescribed.
For this PDSA cycle, the 30 members who were 60 and older and taking 10 or
more prescribed or non-prescribed medications were identified from a panel of 80
members by this project leader. This means that 38%, or a little more than one out of
every three members in the providers panel met the criteria for polypharmacy. The high
prevalence of polypharmacy indicates the importance of implementing this deprescribing
pathway.
A primary goal of this QI project was a 10% improvement (reduction) in the
number of prescribed and non-prescribed medications. The deprescribing process
effectively changed the number of medications taken by 18.8% from the reachable nine
members, which exceeded the goal of 10%. A reduction in number of medications taken
has shown to increase compliance, improve quality of life and members being more
active with activity of daily living. Many of the older adults has initially reports concerns
on being on several medications and were ready to have at least one medication deprescribed and did not report concern regarding this decision. The success of the 18.8%
reduction in medications were largely due to the nine reachable PCPs willingness to
accept the recommended changes.

Although the project was successful for those individuals who could complete the
pathway, the majority of eligible members (70%) were not able to complete the pathway.
The primary reason for this was that the project leader was not able to connect with the
primary care physician. The project leader made three attempts for each member at
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different times of the day to widen the likelihood of reaching the PCPs office. The
project leader ed call the provider’s office and the secretary was not reachable or the
provider would get the answering service. At times, the project leader would reach the
secretary and inform them of the deprescribing intervention using the ARMOR tool and
the plan to deprescribe, and requested that the provider return the call to discuss. These
failed attempts made it difficult for the project leader to move on to the last 3 phases of
the ARMOR intervention (minimize, optimize, and reassess) for the majority of eligible
patients.
Plausible explanations for the difficulties in reaching the PCP could be ascribed to
not enough buy-in and possible system failures between the managed care organization
and the PCP’s office. Many of the PCPs do not understand the role of the managed care
advance practice clinicians in the patient care, in addition to the members seeing their
PCPs. If more collaboration were in place in the form of quarterly or semiannual
meetings between the organization stakeholders (medical director, clinical manger and/or
the program director) this could potentially help the organization work together to
improve patient outcomes. Furthermore, the low response rate of the PCPs could also be
associated with possible high caseload and time constraint from the PCP. Finally, the
excess time needed to safely de-prescribe, as well as the complexity in discussing these
complex members can add some hesitancy and limitation in deprescribing. Formalizing
and streamlining communication for deprescribing between the managed care advanced
practice nurse and PCP could help alleviate this issue.
This pre-pilot, or first PDSA cycle, was implemented by the project leader who is
an advanced practice provider at the managed care organization. Many important lessons
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were learned including the high prevalence and magnitude of polypharmacy among the
patients. The initial chart audit of all 30 members showed a total of 602 prescribed and
non-prescribed medications. Of the nine members who completed the entire pathway,
there were a total of 203 prescribed and non-prescribed medications.
For future PDSA cycles, it would be beneficial to scale-up use of the
deprescribing pathway and include all members, care partners and advance practice
clinicians (APCs) in fully utilizing the pathway. To do that, staff, including APCs,
stakeholders, pharmacists, and care partners, would need to be oriented to the tool. One
way to do that could be a 30-minute in-service of the ARMOR tool implementation
during one of the weekly two hours Interdisciplinary Team (IDT) meeting. Important
messaging that could be integrated into this educational initiative include but are not
limited to:
➢ A large amount of evidence-based literature supports the risks of
polypharmacy and an already established tool like the ARMOR tool has
been shown to be successful in multiple populations (Haque, 2009).
➢ There is a high prevalence of polypharmacy in the site managed care
organization. The ARMOR tool implementation was effective in
identifying prescribing of inappropriate medications for all the nine
members who completed the entire pathway. This finding is aligned with
the published literature.
➢ Provider can successfully identify polypharmacy, assess inappropriate
meds and opportunities for deprescribing using similar tools like the
ARMOR.
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➢ The results revealed medication reconciliation is necessary, using an
evidence-based tool in older adult to help expose prescribing of potentially
inappropriate medication.
Conclusion
Polypharmacy is a public health crisis particularly among older adults with
numerous comorbidities and who are socioeconomically challenged. Implementing an
interdisciplinary deprescribing pathway that utilized the ARMOR tool was effective in
reducing polypharmacy in this managed care organization in a population that was
diverse and socioeconomically disadvantaged. The primary challenge to deprescribing
utilizing the pathway was care coordination between the managed care organization and
the primary care provider. Despite these caveats however, this project demonstrated that
when a standardized deprescribing pathway which utilized the ARMOR tool is used in
eligible managed care patients, and if the patients can be brought through the full
pathway, deprescribing is possible. Improving collaboration with primary care providers
would be critical to improving the number of patients who could benefit from the
intervention.
It is also be important to continue research in this area. Interventions focusing on
polypharmacy are complex and lack broad evidence of effectiveness. Although research
has showed some optimistic results with the utilization of the ARMOR tool, there is no
set guidelines for deprescribing, and implementation is complex as noted in this project.
Additional research should be done that focus on different patient populations with
polypharmacy to strengthen the evidence base of the ARMOR tool in deprescribing and
polypharmacy reduction.
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Appendix A
Table A1: Summary Table
Number of studies

Study intervention

Leve/Quality of study

Findings

VB

46% of the PIMs identified in the cohort, providers
chose to either discontinue the medication, or change
the medication to a safer dose, or safer medication

Intervention: Deprescribing protocol
Bilyeu et al (2011)

Haque, R. (2009)

Sechana et al. Rashmi,
(2020)

Witticke et al., (2013)

An algorithm to guide the staff during medical
assessment and medication reconciliation upon
admission
The use of the ARMOR tool in a LTC facility with
an interdisciplinary team–based approach.

Evaluation of the common reasons of admission,
comorbidies, and echocardiography and to assess
this polypharmacy using ARMOR TOOL

The aim of the study was to investigate the
prevalence of medication regimen characteristics
that are known to reduce patient adherence to
drug therapy. Furthermore, we assessed to what
extent complex medication regimens can possibly
be simplified through different strategies.

V (Quality Improvement)

V, In this study, classified the age group
into four categories that is 60-69, 70-79, 8089 and 90-99 years

The application of the ARMOR tool has led to a
considerable reduction in polypharmacy, reduction of
cost of care, and decrease in hospitalization. Falls and
behaviors with potential of harm to self and other
residents also showed a decline in frequency.

Careful and thoughtful drug prescription strategy
seems to be able to eliminate most of the cases of
polypharmacy even in patients who are suffering with
multiple disorders.

V
Almost one-fifth of all regimen complexity
characteristics relevant for patient adherence were
avoidable by simple modifications of the medication
scheme, stressing the need for targeted interventions.
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Appendix B
Figure: Force Field Analysis

Prescriber specific
factors
Heavy workload and
inexperience with certain
guidelines

Sociocultural

Patient
forgetting to remove and
replace old medications.

Inadequate and lack of
understanding

Using OTC meds with
no indications

Not effectively evaluating chart
Language Barriers
Lack of communications regarding
new and D/C medications

Complicate medication regimen
and poor health literacy

Difficulties using EHR

Lack of an electronic record system that
interface prescription and clinical data.

Focus on individual vs
system.

Policies not in place for
polypharmacy

Limited alternatives
High workload

Methods/Procedures

Organizational

Cause and Effect:
Polypharmacy
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LOGIC MODEL

Problem: The current system has no consistent and reliable method in keeping track of older adults
that are on 10 medications or more, assessing the risks of polypharmacy and assessing for
deprescribing needs when necessary using a stepwise approach.

AIMS: The overall aim of this quality improvement was to decrease polypharmacy and the
prescription of inappropriate medications among older adults enrolled in a community-based care
program. The overarching goal was to design, implement and evaluate a deprescribing pathway, and
empower prescribing clinicians in using the ARMOR tool.

Short Term:
Providers need to review all
medications at each visit
including herbal products,
supplements, and over-thecounter products.
If a medication has no clear
indication must be
discontinued.
Intermediate:

Resources:
Pharmacist
Community Clinician
Electronic health record.
Resources
Caregiver and patient
motivation.
Primary Care
Time

Activities:
Define deprescribing
protocol.
Adapt the ARMOR tool.
Adapt deprescribing and Beer
protocol into current process.
Assess each drug and identify
patients on 10 and more
medications and prioritize
drugs for discontinuation.

Outputs:
Develop a collaborative
workflow between APC,
pharmacist, and PCP to
monitor members that meet
the criteria for deprescribing.
Documentation of adherence.
Documentation of members
responses with protocol.

Educated the patients about
drugs in detail before
initiating a new medication.
Reduction of adverse events
related to polypharmacy.
Long Term:
Starting the conversation
between providers and
interdisciplinary team on
the danger of polypharmacy

Improvement in member’s
Rationales and Assumptions: Older adults that are on multiple medications are at increased risks of adverse drugand
events,
increase morbidity
and mortality and decrease quality of life
provider
experience
Imbedding the American Geriatrics Society Beer Criteria Into the pharmacist current initiative will help identify older adults that are on more than five medications and can benefits from deprescribing.

Reduction in admits and
readmits
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APPENDIX E

● Beers criteria
● -blockers
● Pain medications
● Antidepressants
● Antipsychotics
● Other psychotropics
● Vitamins and supplements
● Drug–disease interactions
● Drug–drug interactions
● Adverse drug reactions

A

Assess

R

Review

M

Minimize

● Number of medications according to functional status
rather than evidence-based medicine

O

Optimize

● For renal/hepatic clearance, PT/PTT, -blockers,
pacemaker function, anticonvulsants, pain medications, and
hypoglycemics; gradual dose reduction for antidepressants
Functional/cognitive status in 1 week and as needed ●
Clinical status and medication compliance

Reassess

R
Source: From Haque R. ARMOR: a tool to evaluate polypharmacy in elderly persons
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APPENDIX F
Evidence of the following ARMOR activities in the patient's record
Care Partner

ID/Gender

MS1356/Male
LS5661/Male
MK4670(F
CL73062/F
GM11154(F)
DM12672(F)
OM22470(M)
MC72162(F)
NG73063(F)
NH82462(F)
KJ31964(F)
NK11759(F)
FG41456(M)
MJ21151(M)
JB121250(M)
MC113050
CA03201961
AB05091950
DC05101936
JW06261961
PQ12081960
HM01081961
MW406191
CJ04061966
OW04191961
AJ11221953
PM0131966
GW1954
IJ3251960
SB05101946
GM08141960

APC Assess

APC Review

Minimize

Optimize

Pt
brought
anti
to
depresse
huddle # medications b-blocker nts
y/n
#
y/n
y/n

psychotr
vit
opic
Respiratiory supplem
meds
medication ents
y/n
y/n

drug to
drug
interacti
ons
y/n

all
indicated
?
y/n

rec to
decrease
meds
y/n

was pt specific
parameters
reviewed?

Was PCP
called for
review
and rec

did PCP
agree w
was visit
recommend scheduled
ations
with Pt

Did
pt/caregiver
agree w
recommendati
ons

YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES

Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
N
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
N
N
N

Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
Y

N
N
N
Y
Y
N
Y
Y
Y
N
N
N
Y
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
N
N
N
N
N
N
N
N
N
N

Y
YES(chronic low BP
BP)
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

Y
Y
N
Y
Y
N
N
Y
Y
Y
Y
N
UTR
Y
Y
UTR
UTR
UTR
UTR
UTR
UTR
UTR
UTR
UTR
UTR
UTR
UTR
UTR
UTR
UTR
UTR

Y Pt agreed
Y Pt agreed
NA
Y Pt agreed
Y Pt agreed
NA
NA
Y Pt agreed
UTR
Y Pt agreed
Y Pt agreed
N
na
Y Pt agreed
Y Pt agreed
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA

Note:UTR=Unable to reach

19 Y
14 N
32 Y
31 Y
33 N
19 N
10 N
17 Y
18 N
18 Y
39 Y
35 Y
39 Y
12 Y
20 Y
10 N
23 Y
8N
14 Y
19 Y
10 Y
24 Y
21 Y
15 Y
23 Y
12 Y
10 Y
17 N
12 Y
18 Y
10 N

Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
N
N

N
N
Y
Y
Y
Y
Y
Y
N
N
N
N
N
N
Y
N
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
N
N
Y
Y
Y

Y
Y
Y
N
Y
Y
Y
Y
N
N
N
N
Y
N
N
N
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

Y
Y
N/A
Y
Y
N
N
Y
N
Y
Y
N
N
Y
Y
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N

Reassess
did APC
review
functional
status after
# meds
deprescribing post

Y
y
N
Y
Y
NA
NA
Y
N
Y
Y
N
na
Y
Y
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA

OUTCOME

Change # %
meds
improve
pre/post ment
Comments

14
13
32
28
30
19
10
16
18
15
30
35
39
10
14
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA

5
1
0
3
3
0
0
1
0
3
9
0
0
2
6

26%
7%
0%
7%
10% Patient was hospitalized for UTI
0%
0%
6%
0%
20% Patient has had multiple amissio
30%
0%
0%
20%
43%
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Polypharmacy ARMOR Deprescribing pathway
Step 1
Project leader reviewed a panel of 80 members and identifies 30 complex members that are 60 years
and older and on 10 medications or more and bring them for discussions to morning huddle.

Step 2
Project leader Assess member’s total medications and identified certain groups of medications such as
beta blockers, pain medications, antipsychotics or psychotropics medications, vitamins and
supplements, common OTC/ prescription interactions (antacid medications, iron supplements, thyroid
medications, members on both coumadin and aspirin, any duplication of medications and any
medications that was added to treat side effects of another medications

Step 3
Project leader Review possible drug-drug interactions, impact of functional status, subclinical adverse
drug reactions were weighed for individual medication benefits against appetite, mood, weight, pain,
activity level.

Step 4
When deprescribing was needed for unnecessary/redundant/unsafe medications, the project leader
collaborated with the primary care provider and made recommendations for Minimizing and
Optimizing the medications the member was on.

Step 4a

Step 4b

For the individuals whose primary care
provider were not able to be reached, the
individual continued their medications

For those the primary care provider agreed with
the deprescribing plan, the project leader
scheduled a visit with the member and/or
caregiver to discuss medication changes.

Step 5
After the scheduled visit, project leader contacted the primary Care Provider within 48 to 72
hours and discussed the outcome of visit.

Step 6
Project leader scheduled follow up visit with
member within 1-2 weeks to monitor
member’s blood pressure, heart rate, bowel
pattern, fall risk, appetite, and sleep.
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Table: Clinical Quality Improvement Checklist

APPENDIX F

CLINICAL QUALITY IMPROVEMENT CHECKLIST
Date:11/4/2020

Project Leader: Johanne Cazeau

Implementation of the Beers Criteria and Deprescribing-Based Educational Intervention tool
among older Adults.

Project Title:

Institution where the project will be conducted: Commonwealth Care Alliance South POD
Instructions: Answer YES or NO to each of the following statements about QI projects.
The specific aim is to improve the process or deliver of care with established/ accepted practice standards,
or to implement change according to mandates of the health facilities’ Quality Improvement programs.
There is no intention of using the data for research purposes.
The project is NOT designed to answer a research question or test a hypothesis and is NOT intended to
develop or contribute to generalizable knowledge.
The project does NOT follow a research design (e.g. hypothesis testing or group comparison
[randomization, control groups, prospective comparison groups, cross-sectional, case control]). The
project does NOT follow a protocol that over-rides clinical decision-making.
The project involves implementation of established and tested practice standards (evidence-based
practice) and/or systematic monitoring, assessment or evaluation of the organization to ensure that
existing quality standards are being met. The project does NOT develop paradigms or untested methods
or new untested standards.

YES
X
X

X

X

The project involves implementation or care practices and interventions that are consensus-based or
evidence-based. The project does NOT seek to test an intervention that is beyond current science and
experience.

X

The project has been discussed with the QA/QI department where the project will be conducted and
involves staff who are working at, or patients/clients/individuals who are seen at the facility where the
project will be carried out.

X

The project has NO funding from federal agencies or research-focused organizations and is not receiving
funding for implementation research.

X

The clinical practice unit (hospital, clinic, division, or care group) agrees that this is a QI project that will
be implemented to improve the process or delivery of care

X

The project leader/DNP student has discussed and reviewed the checklist with the project Course
Faculty. The project leader/DNP student will NOT refer to the project as research in any written or oral
presentations or publications.

NO

X

ANSWER KEY: If the answer to ALL of these questions is YES, the activity can be considered a Clinical Quality
Improvement activity that does not meet the definition of human research. UMB IRB review is not required. Keep a

